GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Short Percentage of Float

ACADIA Pharmaceuticals (FRA:DR6) Short Percentage of Float


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of ACADIA Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Short Percentage of Float falls into.


ACADIA Pharmaceuticals (FRA:DR6) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Short Percentage of Float
Comparable Companies
ARWR ACLX CGON SMMT MLTX APGE MRUS IDYA FOLD XENE OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
ACAD:USA
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Website
https://www.acadia-pharm.com
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (FRA:DR6) Headlines

No Headlines